Normosang (Human Hemin)

Human hemin, the active ingredient in Normosang, is a heme (hemin) presented as a lyophilized powder for solution for injection for intravenous use. It provides exogenous heme to patients experiencing acute attacks of hepatic porphyrias, including acute intermittent porphyria, hereditary coproporphyria, variegate porphyria and other acute hepatic porphyrias.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product integrity through validated cold‑chain logistics and comprehensive quality assurance.

Normosang is used to manage acute hepatic porphyria attacks by supplying exogenous heme to the heme biosynthetic pathway. - Acute intermittent porphyria: reduces the severity and duration of acute neurovisceral attacks. - Hereditary coproporphyria: helps normalize porphyrin precursor levels during crises. - Variegate porphyria: mitigates acute symptoms by down‑regulating ALAS1 activity. - Other acute hepatic porphyrias: provides symptomatic relief during acute episodes.

Administration of Normosang may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Fever or chills: transient temperature rise following infusion. - Nausea or vomiting: gastrointestinal discomfort after administration. - Headache: mild to moderate headache reported post‑dose. - Injection site pain: local discomfort or erythema at the infusion site.

Serious or Rare Side Effects: - Acute hemolysis: rapid destruction of red blood cells, especially in G6PD‑deficient patients. - Thromboembolic events: rare clot formation in veins or arteries. - Severe allergic reaction: anaphylaxis or hypersensitivity requiring immediate medical attention. - Renal impairment: acute kidney injury observed in isolated cases.

Prior to prescribing Normosang, clinicians should consider several safety and handling precautions to minimize risk. - Assess G6PD status: avoid use in patients with glucose‑6‑phosphate dehydrogenase deficiency due to hemolysis risk. - Monitor liver function: evaluate hepatic enzymes before and during therapy. - Observe for hypersensitivity: discontinue infusion if signs of anaphylaxis appear. - Adjust for renal function: use caution in patients with pre‑existing kidney disease. - Review concomitant porphyrin‑inducing drugs: avoid agents that may exacerbate porphyria. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, influencing efficacy or safety; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Barbiturates and carbamazepine: strong porphyrin‑inducing agents that may worsen attacks. - Hormonal contraceptives containing estrogen: can precipitate porphyria crises. - Alcohol: excessive intake may increase porphyrin precursor accumulation.

Moderate Interactions (Monitor Closely): - Anticonvulsants such as phenytoin: may require dose adjustment. - Antifungal azoles (e.g., ketoconazole): potential to affect heme metabolism. - Iron supplements: monitor iron status as hemin provides iron load.